CSIMarket
 
Telomir Pharmaceuticals Inc   (NASDAQ: TELO)
 

Telomir Pharmaceuticals Inc's Customers Performance

TELO



 
TELO's Source of Revenues

• List of TELO Customers




for the same period Telomir Pharmaceuticals Inc

• List of TELO Customers





Telomir Pharmaceuticals Inc's Comment on Sales, Marketing and Customers





  News about Telomir Pharmaceuticals Inc Contracts

Telomir-1: Unlocking the Secrets of Cellular Aging -Telomir Pharmaceuticals Presents Groundbreaking Pre-Clinical Data at Global Longevity Federation Conference

The press release highlights that the upcoming poster presentation at the conference will unveil the promising results of Telomir-1 in elongating telomere caps on human normal embryonic fibroblast cells. These telomere caps, located at the ends of chromosomes, serve as protective layers that prevent the erosion and degradation of genetic material during cell division. As cells age and divide, telomeres gradually shorten, leading to various age-related diseases and a decline in overall health. By extending telomeres, Telomir-1 aims to address this fundamental component of cellular aging and potentially slow down the aging process itself.According to the available information, Telomir Pharmaceuticals conducted...

Telomir Pharmaceuticals Pioneering Age Reversal Science with Breakthrough AI Testing Models

In the perpetual pursuit of the fountain of youth, Telomir Pharmaceuticals is pioneering a groundbreaking approach to age reversal science. Leveraging the power of artificial intelligence (AI) testing models, the company s lead product candidate, Telomir-1, has demonstrated remarkable potential in extending DNA telomeres to reverse age-related conditions. This breakthrough development heralds a new era of possibilities for those seeking effective anti-aging solutions.Telomeres, protective caps at the end of our DNA strands, play a crucial role in maintaining cell longevity and preserving genetic information. As cells divide, these telomeres gradually shorten, leading to age-related ailments such as cardiovas...

Revolutionary Breakthrough: Telomir-1 Shows Promising Pre-Clinical Data in Elongating Telomeres and Targeting Age-Related Inflammatory Conditions

Telomir Pharmaceuticals Presents Exciting Pre-Clinical Data on Telomir-1 at Singapore ConferenceTelomir Pharmaceuticals, in collaboration with Frontage Laboratories, recently unveiled groundbreaking pre-clinical data on their lead development product, Telomir-1, at a prestigious Singapore conference. Telomir s poster presentation captivated the audience, highlighting the product s remarkable ability to elongate telomere caps on human stem cells and effectively target age-related inflammatory conditions. This groundbreaking research opens the door to a potential revolution in the treatment of various age-related diseases.Telomeres, the protective caps at the ends of chromosomes, play a crucial role in maintai...












TELO's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Telomir Pharmaceuticals Inc 71.79 0.00 -5.88 2
SUBTOTAL 0.00 0.00 0.00 -

Sources: Telomir Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Telomir Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Telomir Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.